scholarly journals Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes

2017 ◽  
Vol 52 (10) ◽  
pp. 1268-1275 ◽  
Author(s):  
Don B. Sanders ◽  
Qianqian Zhao ◽  
Zhanhai Li ◽  
Philip M. Farrell
Keyword(s):  
Cystic Fibrosis ◽  
Long Term Outcomes ◽  
Poor Recovery ◽  
Pulmonary Exacerbations

Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation

2018 ◽  
Author(s):  
Andrea Gramegna ◽  
Martina Contarini ◽  
Stefano Aliberti ◽  
Giovanni Sotgiu ◽  
Manuela Seia ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Long Term Outcomes ◽  
Residual Function ◽  
Clinical Worsening

scholarly journals Palivizumab and Long-term Outcomes in Cystic Fibrosis

PEDIATRICS ◽  
2019 ◽  
Vol 144 (1) ◽  
pp. e20183495
Author(s):  
Aliza K. Fink ◽  
Gavin Graff ◽  
Carrie L. Byington ◽  
Deena R. Loeffler ◽  
Margaret Rosenfeld ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Long Term Outcomes

scholarly journals Use of dornase alfa in cystic fibrosis: an Audit of Italian specialists

2021 ◽  
Author(s):  
Sonia Volpi ◽  
Vincenzo Carnovale ◽  
Carla Colombo ◽  
Valeria Raia ◽  
Francesco Blasi ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Lung Function ◽  
Delphi Method ◽  
Therapeutic Use ◽  
Long Term Outcomes ◽  
Progressive Decline ◽  
Dornase Alfa ◽  
Modified Delphi ◽  
Appropriate Prescribing

Background: The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient’s lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients. Method: A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF. Results: Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice. Conclusions: Modified Delphi method was used to define the most appropriate use of dornase alfa in routine CF to improve lung function and long-term outcomes in patients, in agreement with international guidelines on CF management.

Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents with Cystic Fibrosis

2021 ◽  
Author(s):  
Stephanie Bui ◽  
Alexandra Masson ◽  
Raphaël Enaud ◽  
Léa Roditis ◽  
Gaël Dournes ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Real Life ◽  
Long Term Outcomes
Sign in / Sign up

Export Citation Format

Share Document